                Figure 7.  Effect of tumor EPOR-R129C expression on in vivo ERK1/2 phosphorylation, Ki67 proliferation antigen expression, microvessel density and hypoxia.Sections of pCR3.1 vector control and EPOR-R129C mammary fat pad tumors were analyzed by immunocytochemistry as described in Materials and Methods. (A–C) Phospho-ERK, (D) Ki67, (E) CD31, and (F) Pimonidazole hypoxia marker. #P&lt;0.0001;*P = 0.0006; †P = 0.0008; § P = 0.026.

